Search research articles
Contact Us
Filters
Showing results (51-60 of 89) with videos related to
Page
of 9
Sort By:
Biochemical and Biophysical Research Communications
|
March 16, 1992
Importance of secondary structure for endothelin binding and functional activity
R L Panek, T C Major, D G Taylor, et al.
Irish Journal of Psychological Medicine
|
April 29, 2021
Consultant psychiatrists' experience of the impact of the COVID-19 pandemic on mental health services
E Kelleher, E H Geary, M Tawfik, et al.
Life Sciences
|
January 1, 1996
In vitro assessment of oral delivery for hexapeptide endothelin antagonists
B H Stewart, E L Reyner, E Tse, et al.
Journal of Applied Microbiology
|
July 16, 2003
The prevalence and spread of Escherichia coli O157:H7 at a commercial beef abattoir
J M McEvoy, A M Doherty, J J Sheridan, et al.
Journal of Medicinal Chemistry
|
October 23, 1998
Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity
S R Eaton, W L Cody, A M Doherty, et al.
Life Sciences
|
March 6, 1998
Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor
B L Batley, A M Doherty, J M Hamby, et al.
Journal of Medicinal Chemistry
|
July 4, 1997
Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties
W L Cody, J X He, M D Reily, et al.
Biochemical and Biophysical Research Communications
|
April 17, 1995
Pharmacological differences between rat and human endothelin B receptors
E E Reynolds, O Hwang, M A Flynn, et al.
Bioorganic & Medicinal Chemistry
|
September 1, 1995
Structure-activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3-kinase with PDGF-beta receptor
K Ramalingam, S R Eaton, W L Cody, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 12, 1998
In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
R L Panek, G H Lu, S R Klutchko, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 89) with videos related to
Sort By:
Page
of 9
Biochemical and Biophysical Research Communications
|
March 16, 1992
Importance of secondary structure for endothelin binding and functional activity
R L Panek, T C Major, D G Taylor, et al.
Irish Journal of Psychological Medicine
|
April 29, 2021
Consultant psychiatrists' experience of the impact of the COVID-19 pandemic on mental health services
E Kelleher, E H Geary, M Tawfik, et al.
Life Sciences
|
January 1, 1996
In vitro assessment of oral delivery for hexapeptide endothelin antagonists
B H Stewart, E L Reyner, E Tse, et al.
Journal of Applied Microbiology
|
July 16, 2003
The prevalence and spread of Escherichia coli O157:H7 at a commercial beef abattoir
J M McEvoy, A M Doherty, J J Sheridan, et al.
Journal of Medicinal Chemistry
|
October 23, 1998
Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity
S R Eaton, W L Cody, A M Doherty, et al.
Life Sciences
|
March 6, 1998
Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor
B L Batley, A M Doherty, J M Hamby, et al.
Journal of Medicinal Chemistry
|
July 4, 1997
Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties
W L Cody, J X He, M D Reily, et al.
Biochemical and Biophysical Research Communications
|
April 17, 1995
Pharmacological differences between rat and human endothelin B receptors
E E Reynolds, O Hwang, M A Flynn, et al.
Bioorganic & Medicinal Chemistry
|
September 1, 1995
Structure-activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3-kinase with PDGF-beta receptor
K Ramalingam, S R Eaton, W L Cody, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 12, 1998
In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
R L Panek, G H Lu, S R Klutchko, et al.
Page
of 9